Antibody Characterization

Antibody Characterization

Antibody Characterization

Fusion Antibodies is proud to introduce our antibody analysis services, to support diagnostic and therapeutic antibody development.

Fusion Antibodies have developed in silico and in vitro approaches to analyse key properties of your antibodies and recombinant proteins. All of the services listed here are available stand alone or as part of a larger Antibody Developability by Design service.

In vitro antibody analysis services

Fusion Antibodies offer a range of in vitro antibody analysis services, available as stand-alone studies or in combination with other services.

Target Binding Analysis

  • SPR (including kinetic analysis)
  • BLI (including kinetic analysis)



  • Size exclusion chromatography analysis (SEC)
  • Differential scanning fluorimetry analysis (DSF)
  • Affinity-capture self-interaction nanoparticle spectroscopy analysis (AC-SINS)
  • Hydrophobic interaction chromatography analysis (HIC)



  • Spectroscopy (OD280)
  • IgG quantification by bio-layer interferometry (BLI)
  • Chromatography (Protein A)

Effector Function

  • FC receptor binding analysis by ELISA or bio-layer interferometry (BLI)



  • SDS PAGE analysis
  • Residual protein A, host cell proteins (HCP) and DNA assays
  • Reverse Phase Interaction Chromatography
  • Endotoxin analysis (LAL test)


Charge Variants

  • Ion exchange chromatography analysis (IEC)



  • LabChip GXII characterization

In silico antibody analysis services

Fusion Antibodies offer a suite of in silico antibody analysis services, which uses cutting edge software to examine the primary sequence and tertiary structure of your antibody or recombinant protein. These analyses probe the target affinity, immunogenicity and manufacturability of your antibody. Each of the below services can be used to analyse  particular characteristics of your antibody of interest or are available as part of an antibody developability by design (ADD) service package.


1. Antibody immunogenicity screen

Evaluate the potential of your antibody to provoke an immune response in patients by screening for T-cell epitopes. Compare your antibody to all known germlines for similarity.


2. In silico primary antibody sequence liability analysis

Screen for sequence liabilities which can result in complications in downstream manufacturing.

  • in silico isomerization site analysis
  • in silico free cysteine analysis
  • in silico charge variant analysis
  • in silico glycosylation site analysis
  • in silico deamidation site analysis
  • in silico oxidation site analysis
  • in silico proteolytic site analysis


3. In silico antibody stability analysis

Analyze the stability of the antibody under different conditions and determine the isoelectric point.


4. In silico antibody aggregation and hydrophobicity analysis

Antibody aggregation can lead to manufacturing difficulties and also increased risk of immunogenicity reactions in patients. This analysis creates a hydrophobicity map of the antibody to help identify areas that may trigger aggregation.

Contact us today

Fusion Antibodies